Physician profile
Scariya M Kumaramangalam
NPI 1417996372
$440,221.51
in general payments reported to CMS, 2019-2025
36 companies · $105K in 2025
The $105K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $32K · 2021: $34K · 2022: $56K · 2023: $84K · 2024: $90K · 2025: $105K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $176K · Consulting Fee: $61K · Food and Beverage: $15K · Honoraria: $14K · Travel and Lodging: $14K · Education: $54.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $176,025.00 |
| Consulting Fee | $60,550.00 |
| Food and Beverage | $15,209.48 |
| Honoraria | $14,025.00 |
| Travel and Lodging | $13,992.49 |
| Education | $54.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $143,002.60 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $118,079.85 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $72,187.58 | 2022-2025 | Auvelity, Sunosi |
| Allergan, INC. | $66,198.37 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $27,019.06 | 2020-2025 | Fanapt |
| Alkermes, INC. | $2,792.51 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,828.93 | 2019-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,756.49 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $1,422.26 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $1,256.66 | 2019-2022 | |
| Corium, LLC | $560.93 | 2022-2025 | Azstarys |
| Avanir Pharmaceuticals, INC. | $529.97 | 2019-2022 | |
| Neos Therapeutics, Lp | $377.19 | 2019-2024 | Adzenys Xr-Odt |
| Lundbeck LLC | $358.20 | 2019-2025 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $345.26 | 2025 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $309.15 | 2021-2025 | Wegovy |
| Ironshore Pharmaceuticals INC. | $250.35 | 2019-2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $239.33 | 2022-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $218.16 | 2019-2024 | Trintellix |
| Ucb, INC. | $191.38 | 2019-2025 | Nayzilam |
| E.R. Squibb & Sons, L.L.C. | $167.00 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $142.01 | 2019-2021 | |
| Grifols USA, LLC | $141.73 | 2019 | |
| Lilly USA, LLC | $124.99 | 2024 | Kisunla |
| Tris Pharma INC | $124.75 | 2023-2024 | Dyanavel Xr, Quillichew Er, Quillivant |
| Collegium Pharmaceutical, INC. | $124.26 | 2025 | Jornay Pm |
| Sk Life Science, INC. | $114.35 | 2021 | |
| Almatica Pharma LLC | $109.60 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Eisai INC. | $61.11 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $45.02 | 2019 | |
| Supernus Pharmaceuticals, INC. | $44.36 | 2022 | |
| Merck Sharp & Dohme LLC | $21.18 | 2021 | |
| Acadia Pharmaceuticals INC | $21.18 | 2025 | Nuplazid |
| Neuronetics, INC. | $21.06 | 2020 | |
| Noven Therapeutics, LLC | $17.88 | 2024 | Xelstrym |
| Bausch Health US, LLC | $16.80 | 2025 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scariya Kumaramangalam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.